银诺医药-B用于治疗2型糖尿病的核心产品于澳门的首张处方已在澳门华宝医疗中心开出

Core Insights - The company is actively advancing the global expansion of its core product, Isupravaglutide α, which is intended for the treatment of Type 2 Diabetes (T2D) [1] - The company received BLA (Biologics License Application) approval for its core product in the Macau Special Administrative Region of the People's Republic of China in June 2025 [1] - The first prescription for the core product for T2D treatment was issued at the Huabao Medical Center in Macau on September 12, 2025, marking the official commercialization phase of the product in Macau [1]